CDNA Share Price Performance
US$17.89
-1.03 (-5.44%)
22.2% undervalued intrinsic discount
US$23.00
Fair Value
Price US$17.89
AnalystConsensusTarget US$23.00
AnalystLowTarget US$20.00
AnalystHighTarget US$26.00
Fair ValueUS$23.00
Share Pricen/a
CareDx, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 8 Fair Values set on narratives written by author
CDNA Community Narratives
AN
Fair Value US$23 22.2% undervalued intrinsic discount
Rising Organ Transplant Demand And AI Diagnostics Will Create Opportunity
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value US$20 10.5% undervalued intrinsic discount
New Medicare Policies Will Erode Margins Despite Digital Gains
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$26 31.2% undervalued intrinsic discount
AlloSure And AlloMap Will Boost Molecular Transplant Care Despite Hurdles
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
New Medicare Policies Will Erode Margins Despite Digital Gains
Key Takeaways Imminent shifts in reimbursement policies and industry consolidation threaten CareDx's pricing power, gross margins, and future revenue scalability. Growing regulatory scrutiny and increased competition in transplant diagnostics may slow market share gains and place long-term pressure on earnings momentum.Read more
14
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$20
10.5% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Profit Margin
10.26%
Future PE
17.93x
Price in 2029
US$24.5
AlloSure And AlloMap Will Boost Molecular Transplant Care Despite Hurdles
Key Takeaways Breakthroughs in AI-driven diagnostics, digital health expansion, and strong clinical validation position CareDx for outsized revenue growth and margin acceleration beyond current forecasts. Advanced digitization and integration with major healthcare platforms streamline operations, enhancing net margins, cash flow, and creating sticky, high-margin recurring revenue streams.Read more
12
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$26
31.2% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
14.15% p.a.
Profit Margin
0.51%
Future PE
485.14x
Price in 2029
US$31.62
Rising Organ Transplant Demand And AI Diagnostics Will Create Opportunity
Key Takeaways Growing demand for core testing services and expansion into AI-driven diagnostics and digital health are driving recurring, high-margin revenue and supporting improved earnings stability. Enhanced payer coverage and operational efficiencies position CareDx for sustained profitability and margin expansion through diversified revenue streams and lower operating costs.Read more
66
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$23
22.2% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
13.24% p.a.
Profit Margin
9.15%
Future PE
24.35x
Price in 2028
US$27.99
Trending Discussion
Recently Updated Narratives
AN
CDNA: Final MolDX LCD Outcome Will Shape Appeal Despite 2026 Guidance
Fair Value: US$20 10.5% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
CDNA: Reimbursement Outcomes Will Drive Future Upside Despite Cautious Rating
Fair Value: US$26 31.2% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
CDNA: Raised Revenue Outlook And Buyback Activity Will Support Bullish Repricing
Fair Value: US$23 22.2% undervalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
CareDx, Inc. Key Details
About CDNA
- Founded
- 1998
- Employees
- 763
- CEO
- WebsiteView website
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.
